A Phase IIb, randomized, multicenter study of the efficacy of GVAX pancreas vaccine and CRS-207 compared to chemotherapy or to CRS-207 alone in adults with previously-treated metastatic pancreatic adenocarcinoma (eclipse study)

نویسندگان

  • Andrea Wang-Gillam
  • Vincent Picozzi
  • Todd Crocenzi
  • Michael Morse
  • Herbert Zeh
  • Robert Fine
  • Aimee Murphy
  • Justin Skoble
  • Edward Lemmens
  • Sandy Ferber
  • Allan Rosen
  • John Grous
  • Thomas W Dubensky
  • Dirk Brockstedt
  • Elizabeth Jaffee
  • Dung Le
چکیده

A Phase IIb, randomized, multicenter study of the efficacy of GVAX pancreas vaccine and CRS-207 compared to chemotherapy or to CRS-207 alone in adults with previously-treated metastatic pancreatic adenocarcinoma (eclipse study) Andrea Wang-Gillam, Vincent Picozzi, Todd Crocenzi, Michael Morse, Herbert Zeh, Robert Fine, Aimee Murphy, Justin Skoble, Edward Lemmens, Sandy Ferber, Allan Rosen, John Grous, Thomas W Dubensky, Dirk Brockstedt, Elizabeth Jaffee, Dung Le

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Long term survivors and immune biomarker analysis of Phase IIa, randomized study of GVAX pancreas and crs-207 immunotherapy in patients with metastatic pancreatic cancer

Methods In a Phase IIa randomized study, patients with metastatic pancreatic ductal adenocarcinoma (PDA) treated sequentially with two vaccine-based immunotherapies demonstrated extended overall survival (OS) with tolerable side effects. Treatment included low-dose cyclophosphamide (CY) followed by GVAX pancreas, an irradiated GM-CSF-secreting allogeneic PDA cell vaccine, and subsequent adminis...

متن کامل

Clinical experience with live-attenuated, double-deleted (LADD) listeria monocytogenes targeting mesothelin-expressing tumors

Immune-based cancer therapies have demonstrated benefit in multiple clinical trials. The interest in using recombinant bacteria as vaccine vectors for active cancer immunotherapy derives in part from their ability to stimulate multiple innate immune pathways and, at the same time, to effectively deliver antigen for presentation to the adaptive immune system. We have developed a vaccine platform...

متن کامل

Updates on first-line therapy for metastatic pancreatic adenocarcinoma.

Pancreatic adenocarcinoma is the 10th most common malignancy in the United States but is responsible for the 4th most cancer related deaths. This disease can only be potentially cured through early discovery and complete surgical resection. Unfortunately, nearly half of patients have metastatic spread at presentation. Combination chemotherapy with FOLFIRINOX or gemcitabine with nab-paclitaxel c...

متن کامل

Novel agents for the treatment of pancreatic cancer.

Metastatic pancreatic cancer continues to be a difficult disease to treat because of its aggressive nature, advanced stage at presentation and lack of treatment options. There is a need for the development of new agents directed against novel targets to improve outcomes for these patients. At the 2014 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium phase I/II tri...

متن کامل

Developing Effective Salmonella-based Approaches to Treat Pancreatic Cancer

Pancreatic ductal adenocarcinoma (PDAC) is predicted to have the second highest incidence of fatalities among all solid tumor malignancies worldwide. Despite three decades of research focused on treating PDAC, the five-year survival rate is less than 6%, thus leaving much room for improvement. Historically, PDAC has been difficult to treat due to the absence of early detection methods resulting...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:

دوره 2  شماره 

صفحات  -

تاریخ انتشار 2014